Simcere group (NXTC) trims NextCure stake, ends 10% beneficial ownership

Rhea-AI Filing Summary

Simcere Zaiming, Inc., together with related reporting entities, reported the sale of 30,000 shares of NextCure, Inc. common stock on 2026-08-10 at $6.16 per share, held indirectly. After this transaction, 308,636 shares of common stock remained indirectly held. The reporting group states that, as a result of this sale, they ceased to be beneficial owners of more than 10% of NextCure’s common stock and therefore are no longer subject to Section 16 reporting for this issuer. Each reporting person disclaims beneficial ownership beyond their pecuniary interest.

Insider Trade Summary

Net Seller: 30,000 shares

Net Sell 1 txn

Insider Simcere Zaiming, Inc., Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., Simcere Zaiming Pharmaceutical Co., Ltd., Simcere Pharmaceutical Group Ltd, Ren Jinsheng, Tang Renhong

Role Insider | Insider | Insider | Insider | Insider | Insider

Sold 30,000 shs ($185K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3	30,000	$6.16	$185K

Holdings After Transaction: Common Stock — 308,636 shares (Indirect, See Footnotes)

Footnotes (3)

1. F1. The securities reported herein were directly held by Simcere Zaiming, Inc. ("Simcere Zaiming") and may be deemed to have been indirectly beneficially owned by the other Reporting Persons.
2. F2. Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. ("Jiangsu Zaiming") is the sole shareholder of Simcere Zaiming. Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.) is the sole shareholder of Jiangsu Zaiming. Simcere Pharmaceutical Group Limited ("Simcere Group") is the controlling shareholder of Simcere Zaiming Pharmaceutical Co., Ltd. through several intermediate companies. Mr. Jinsheng Ren is the chairman of the board of directors of Simcere Group and a director of Simcere Zaiming Pharmaceutical Co., Ltd. Mr. Renhong Tang is a director of Simcere Group, the chief executive officer and chairman of the board of directors of Simcere Zaiming Pharmaceutical Co., Ltd., a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming. Messrs. Ren and Tang may be deemed to be the beneficial owners having shared voting power and shared investment power over the securities described herein.
3. F3. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that any Reporting Person is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.

Key Figures

Shares sold: 30,000 shares Sale price: $6.16 per share Shares remaining indirectly held: 308,636 shares

3 metrics

Shares sold 30,000 shares Common stock sale on 2026-08-10 by Simcere Zaiming, Inc.

Sale price $6.16 per share Price for 30,000 NextCure common shares sold on 2026-08-10

Shares remaining indirectly held 308,636 shares Indirect holdings reported after the transaction

Key Terms

beneficial owner, Section 16, indirectly beneficially owned, pecuniary interest, +1 more

5 terms

beneficial owner regulatory

"they have ceased to be beneficial owners of more than 10% of the Issuer's common stock"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

Section 16 regulatory

"therefore are no longer subject to Section 16 of the Exchange Act"

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

indirectly beneficially owned regulatory

"may be deemed to have been indirectly beneficially owned by the other Reporting Persons"

pecuniary interest financial

"disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest"

indirect ownership regulatory

"The securities reported herein were directly held by Simcere Zaiming, Inc. and may be deemed to have been indirectly beneficially owned"

FAQ

What insider transaction did NXTC disclose from Simcere Zaiming, Inc.?

NextCure (NXTC) disclosed that Simcere Zaiming, Inc. sold 30,000 shares of common stock on 2026-08-10 at $6.16 per share, reported as an indirect ownership transaction involving affiliated entities.

How many NXTC shares does the Simcere group report holding after this sale?

Following the reported sale, the Simcere-related reporting group shows 308,636 shares of NextCure common stock indirectly held. These figures are tied to entities in the Simcere corporate structure, with beneficial ownership subject to their stated disclaimers.

Did the Simcere reporting persons remain 10% owners of NXTC after the transaction?

No. The reporting persons state this Form 4 is an exit filing, as they have ceased to be beneficial owners of more than 10% of NextCure’s common stock and thus are no longer subject to Section 16 reporting for this issuer.

Was the NXTC insider sale made under a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox is not marked, and there is no footnote stating the transactions were made under a trading plan, so the sale is not reported as pursuant to a 10b5-1 arrangement.

Who are the reporting persons in this NXTC Form 4 related to Simcere?

Reporting persons include Simcere Zaiming, Inc. and several related entities plus Jinsheng Ren and Renhong Tang. Footnotes explain the corporate relationships and state that each reporting person disclaims beneficial ownership beyond their pecuniary interest.

Is the Simcere NXTC transaction a direct or indirect ownership change?

The transaction is reported as indirect ownership, with the securities directly held by Simcere Zaiming, Inc. and potentially deemed indirectly beneficially owned by the other reporting persons, subject to their ownership disclaimers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/12/2026 - 11:35 AM Accepted by SEC EDGAR 08/12/2026 - 11:35 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simcere Zaiming, Inc.

(Last) (First) (Middle)

20 ACORN PARK DR.

(Street)

CAMBRIDGE MASSACHUSETTS 02140

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NextCure, Inc. [ NXTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Former 10% Owner

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/10/2026		S		30,000	D	$6.16	308,636	I	See Footnotes(1)(2)(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Simcere Zaiming, Inc.

(Last) (First) (Middle)

20 ACORN PARK DR.

(Street)

CAMBRIDGE MASSACHUSETTS 02140

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Former 10% Owner

1. Name and Address of Reporting Person^*

Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.

(Last) (First) (Middle)

BUILDING 23, NO. 699-18

XUANWU AVENUE

(Street)

NANJING CITY, JIANGSU PROVINCE 210000

(City) (State) (Zip)

CHINA

(Country)

Relationship of Reporting Person(s) to Issuer

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Former 10% Owner

1. Name and Address of Reporting Person^*

Simcere Zaiming Pharmaceutical Co., Ltd.

(Last) (First) (Middle)

NO. 20, YAOGUYIHENG ROAD

XIUYING DISTRICT

(Street)

HAIKOU CITY, HAINAN PROVINCE 570100

(City) (State) (Zip)

CHINA

(Country)

Relationship of Reporting Person(s) to Issuer

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Former 10% Owner

1. Name and Address of Reporting Person^*

Simcere Pharmaceutical Group Ltd

(Last) (First) (Middle)

BUILDING 23, NO. 699-18

XUANWU AVENUE

(Street)

NANJING CITY, JIANGSU PROVINCE 210000

(City) (State) (Zip)

CHINA

(Country)

Relationship of Reporting Person(s) to Issuer

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Former 10% Owner

1. Name and Address of Reporting Person^*

Ren Jinsheng

(Last) (First) (Middle)

BUILDING 23, NO. 699-18

XUANWU AVENUE

(Street)

NANJING CITY, JIANGSU PROVINCE 210000

(City) (State) (Zip)

CHINA

(Country)

Relationship of Reporting Person(s) to Issuer

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Former 10% Owner

1. Name and Address of Reporting Person^*

Tang Renhong

(Last) (First) (Middle)

BUILDING 23, NO. 699-18

XUANWU AVENUE

(Street)

NANJING CITY, JIANGSU PROVINCE 210000

(City) (State) (Zip)

CHINA

(Country)

Relationship of Reporting Person(s) to Issuer

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Former 10% Owner

Explanation of Responses:

1. The securities reported herein were directly held by Simcere Zaiming, Inc. ("Simcere Zaiming") and may be deemed to have been indirectly beneficially owned by the other Reporting Persons.

2. Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. ("Jiangsu Zaiming") is the sole shareholder of Simcere Zaiming. Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.) is the sole shareholder of Jiangsu Zaiming. Simcere Pharmaceutical Group Limited ("Simcere Group") is the controlling shareholder of Simcere Zaiming Pharmaceutical Co., Ltd. through several intermediate companies. Mr. Jinsheng Ren is the chairman of the board of directors of Simcere Group and a director of Simcere Zaiming Pharmaceutical Co., Ltd. Mr. Renhong Tang is a director of Simcere Group, the chief executive officer and chairman of the board of directors of Simcere Zaiming Pharmaceutical Co., Ltd., a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming. Messrs. Ren and Tang may be deemed to be the beneficial owners having shared voting power and shared investment power over the securities described herein.

3. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that any Reporting Person is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.

Remarks:

This Form 4 constitutes an exit filing for the Reporting Persons, as they have ceased to be beneficial owners of more than 10% of the Issuer's common stock and therefore are no longer subject to Section 16 of the Exchange Act as a result of the sale described above.

	Simcere Zaiming, Inc., By: /s/ Renhong Tang, Chief Executive Officer	08/12/2026
	Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., By: /s/ Renhong Tang, Director and Attorney-in-Fact	08/12/2026
	Simcere Zaiming Pharmaceutical Co., Ltd., By: /s/ Renhong Tang, Chief Executive Officer and Chairman of the Board of Directors	08/12/2026
	Simcere Pharmaceutical Group Limited, By: /s/ Jinsheng Ren, Chairman and Executive Director	08/12/2026
	Ren Jinsheng, /s/ Jinsheng Ren	08/12/2026
	Tang Renhong, /s/ Renhong Tang	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)